Art. 5 Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing aut…

Specific obligations

In forcesince 29 Mar 2006cited 6×
1.

By way of specific obligations, the holder of a conditional marketing authorisation shall be required to complete ongoing studies, or to conduct new studies, with a view to confirming that the risk-benefit balance is positive and providing the additional data referred to in Article 4(1).

In addition, specific obligations may be imposed in relation to the collection of pharmacovigilance data.

2.

The specific obligations referred to in paragraph 1 and the timeframe for their completion shall be clearly specified in the conditional marketing authorisation.

3.

The Agency shall make the specific obligations and the timeframe for their completion publicly available.

  • Ordonnance du président du Tribunal du 20 juillet 2016. PTC Therapeutics International Ltd contre Agence européenne des médicaments.Decision

    … 24, 26, 57(1), point (1), 57(2), 76 and 80 of Regulation No 726/2004, Article 4(7) of Regulation No 141/2000 and Articles 5(3), 6(3) and 8 of Regulation No 507/2006 — establish a specific set of rules on transparency and confidentiality, …

    20 Jul 2016 · 62015TO0718(02)

  • Judgment of the General Court (Second Chamber) of 5 February 2018. PTC Therapeutics International Ltd v European Medicines Agency.Decision

    [As rectified by order of 27 April 2018] As regards Regulation No 507/2006, its legal basis being Regulation No 726/2004, that also reflects the legislature’s intention that the MA procedure should be transparent. In addition, the …

    5 Feb 2018 · 62015TJ0718

  • Order of the Vice-President of the Court of 1 March 2017. European Medicines Agency (EMA) v PTC Therapeutics International Ltd.Decision

    In the first place, all documents submitted in connection with an MA application and, in particular, clinical and non-clinical studies, such as the report at issue, should enjoy a general presumption of confidentiality under Regulation No …

    1 Mar 2017 · 62016CO0513

  • Opinion of Advocate General Hogan delivered on 11 September 2019. PTC Therapeutics International Ltd v European Medicines Agency.Decision

    First, the procedures for a conditional MA and that for an unconditional MA are separate in the sense that a request for a conditional MA may be presented according to Article 3 of Regulation No 507/2006 together with the application for …

    11 Sep 2019 · 62018CC0175

  • Arrêt du Tribunal (cinquième chambre) du 23 septembre 2026 (Extraits). Advanz Pharma Ltd contre Commission européenne.Decision

    Article 5(1) of Regulation No 507/2006 is worded as follows: ‘By way of specific obligations, the holder of a conditional marketing authorisation shall be required to complete ongoing studies, or to conduct new studies, with a view to …

    23 Sep 2026 · 62024TJ0455

  • Judgment of the General Court (Fourth Chamber, Extended Composition) of 19 November 2025. SD v European Medicines Agency.Decision

    … 83) и на член 5 от Регламент (ЕО) № 507/2006 на Комисията от 29 март 2006 година за издаване на разрешения за търговия при определени условия …

    19 Nov 2025 · 62022TJ0623